Literature DB >> 23254635

Low-abundant cerebrospinal fluid proteome alterations in dementia with Lewy bodies.

Jana-Katharina Dieks1, Joanna Gawinecka, Abdul R Asif, Daniela Varges, Karin Gmitterova, Jan-Hendrik Streich, Hassan Dihazi, Uta Heinemann, Inga Zerr.   

Abstract

Dementia with Lewy bodies (DLB) is one of the most common neurodegenerative diseases and shares multiple clinical and neuropathological parallels with Alzheimer's (AD) and Parkinson's disease (PD). A variety of clinical signs are suggestive for the diagnosis, and imaging (βCIT SPECT) contributes substantially to the diagnosis. The study reported here was performed in search for a biomarker in the cerebrospinal fluid (CSF) of these patients. We applied 2D fluorescence difference gel electrophoresis and mass spectrometry to analyze the CSF proteome pattern of DLB patients after depleting twelve high-abundant proteins. The densitometric analysis of 2D gels showed the up- or down-regulation of 44 protein spots. Subsequently, 23 different proteins were identified. The majority is involved in acute phase and immune response. Many of these proteins were previously reported before as being associated with AD or PD, which strongly suggests a molecular cross-talk and may explain clinical and pathological overlap of these disease entities. Among the identified proteins are two highly upregulated proteins-inter alpha trypsin inhibitor heavy chain (ITIH4) and calsyntenin 1-that may have the potential to serve as molecular biomarkers specific for DLB. The identification of DLB-associated proteome changes will help to further understand pathological processes occurring in DLB and may provide future prospects to diagnostic and therapeutic options.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23254635     DOI: 10.3233/JAD-121810

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  4 in total

Review 1.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

2.  Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach.

Authors:  Inger van Steenoven; Marleen J A Koel-Simmelink; Leonie J M Vergouw; Betty M Tijms; Sander R Piersma; Thang V Pham; Claire Bridel; Gian-Luca Ferri; Cristina Cocco; Barbara Noli; Paul F Worley; Mei-Fang Xiao; Desheng Xu; Patrick Oeckl; Markus Otto; Wiesje M van der Flier; Frank Jan de Jong; Connie R Jimenez; Afina W Lemstra; Charlotte E Teunissen
Journal:  Mol Neurodegener       Date:  2020-06-18       Impact factor: 14.195

3.  Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies.

Authors:  Madhurima Chatterjee; Inger van Steenoven; Evelien Huisman; Linda Oosterveld; Henk Berendse; Wiesje M van der Flier; Marta Del Campo; Afina W Lemstra; Wilma D J van de Berg; Charlotte E Teunissen
Journal:  Biomolecules       Date:  2020-08-12

4.  Combined proteomic and metabolomic analyses of cerebrospinal fluid from mice with ischemic stroke reveals the effects of a Buyang Huanwu decoction in neurodegenerative disease.

Authors:  Wei-Hsiang Hsu; Yuh-Chiang Shen; Young-Ji Shiao; Ching-Hua Kuo; Chung-Kuang Lu; Tai-Yuan Lin; Wei-Chi Ku; Yun-Lian Lin
Journal:  PLoS One       Date:  2019-01-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.